Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled Phase III Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

NCT05664750 is registered in ClinicalTrials.gov with Zhuhai Trinomab Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05664750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05664750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled Phase III Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus
Lead sponsor
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 22, 2022
Completion date
July 7, 2023
Enrollment
675 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

tetanus